Life Sciences
More
-
CHICAGO, Feb 1- After nearly 100 years, researchers could be on the verge of finding a vaccine that would eradicate tuberculosis infections, a scourge that kills 1.4 million people a year. "In my own personal view, I will consider this to be a landmark or a watershed," said Peggy Johnston, senior program officer at the Bill& Melinda Gates Foundation in Seattle.
-
NEW YORK, Jan 30- Sarepta Therapeutics Inc became the second company in as many days see its shares plunge as a result of a Twitter hoax on Wednesday after a user posed as an influential short-seller and alleged improprieties at the biopharmaceutical company.
-
NEW YORK-- Keryx Biopharmaceuticals Inc. said Tuesday that it will offer $55 million worth of its common stock in a public offering. The company plans to submit an application for approval of the drug to both the U.S. Food and Drug Administration and European regulators in this year's second quarter.
-
Shares of Keryx Biopharmaceuticals Inc. extended its gains Tuesday, a day after the drug developer said its potential kidney disease drug, Zerenex, performed much better than a placebo in a late-stage clinical trial.
-
NEW YORK-- Shares of Keryx Biopharmaceuticals Inc. soared Monday after the drug developer said its potential kidney disease drug, Zerenex, performed much better than a placebo in a late-stage clinical trial.
-
DEERFIELD, Ill.-- Baxter International Inc. said Thursday its net income rose 7 percent in the fourth quarter on greater sales of hemophilia and immune drugs and other injectable therapies. Baxter's fourth-quarter net income rose to $494 million, or 89 cents per share, from $463 million, or 82 cents per share.
-
*4th- qtr profit 89 cents/ share vs 82 cents a year ago. Jan 24- Medical device and bioscience company Baxter International Inc reported higher quarterly earnings on Thursday and forecast sales growth of 10 percent for 2013..
-
Japan has one of the world’s highest suicide rates. But last year the number of suicides fell below 30,000 for the first time in 15 years, thanks in part to community efforts. The CSM reports.
-
*Novartis seeks to sell Bexsero as soon as possible. ZURICH, Jan 22- Novartis won European approval for the first vaccine against meningitis B and is seeking to persuade cash-strapped governments to add it to routine vaccination programs to ensure the drug's commercial success.
-
TRENTON, N.J.-- Biotech drugmaker Amgen Inc. should focus on a strategic acquisition and testing of six potential new drugs when it reports fourth-quarter results after the stock market closes Wednesday.
-
*Sanofi runs out of most vaccine dosages. Sanofi SA, the largest flu vaccine provider in the United States, said on Thursday it had sold out of four of the six different dosages of Fluzone seasonal flu vaccine due to unanticipated demand.
-
Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.
-
MILAN, Jan 3- Italian biopharmaceutical company Philogen has signed a worldwide licence agreement with drug firm Pfizer for the development of Dekavil, an experimental treatment for autoimmune diseases. Under the deal, Pfizer will retain exclusive rights to market any products developed during the collaboration, Philogen said in a statement on Thursday.
-
Dec 17- U.S. health regulators have approved a new four-strain seasonal influenza vaccine made by GlaxoSmithKline Plc, the company said on Monday. The U.S. Food and Drug Administration has approved Fluarix Quadrivalent to immunize children age 3 and older and adults against flu virus subtypes A and B contained in the vaccine.
-
*U.S. consumer sentiment drops, hitting stocks. NEW YORK, Dec 7- The Dow and the S&P 500 advanced modestly on Friday, though another sell-off in Apple depressed technology shares and kept the Nasdaq negative, overshadowing a sharply better-than-expected jobs report.
-
NEW YORK, Dec 7- The S&P 500 eked out only a slight gain on Friday as weak consumer sentiment data offset enthusiasm from a better-than-expected jobs report, while the Nasdaq slipped after some investors resumed a sell-off of Apple shares. Wall Street opened higher after the U.S. Labor Department said non-farm payrolls added 146,000 jobs in November.
-
NEW YORK, Dec 7- The S&P 500 and the Nasdaq slipped on Friday after consumer sentiment unexpectedly dipped, dampening early enthusiasm from a better-than-expected employment report. The Thomson Reuters/ University of Michigan's preliminary consumer sentiment index plunged to 74.5 in early December, the lowest level since August.
-
*Novartis will produce vaccine in new North Carolina plant. Nov 20- The U.S. Food and Drug Administration said on Tuesday it approved a seasonal flu vaccine produced by Novartis using animal cell culture rather than the traditional manufacturing using chicken eggs- a speedier process that could help build stockpiles in the event of a pandemic.
-
Nov 20- The U.S. Food and Drug Administration said on Tuesday it approved a seasonal flu vaccine produced by Novartis using cultured animal cells rather than the traditional manufacturing process that uses fertilized chicken eggs. Similar cell culture technology has long been used to produce other types of vaccines, FDA said.
-
ZURICH, Nov 16- The European Medicines Agency has thrown Novartis' loss-making vaccines business a lifeline by recommending its meningitis B shot for approval, which means the pressure is on to make the product a commercial success.